ReviewFrontiers in immunology2026
Advances in infection-immunity mechanisms and molecular regulatory networks in severe pneumonia-associated lung injury.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Berberine Suppresses Inflammatory Response in Severe Pneumonia by Specifically Targeting Upregulation of SIRT1 to Activate Nrf2 Signaling Pathway.Chinese journal of integrative medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe pneumonia-associated lung injury remains a critical focus in infection and immunology research due to its high lethality and complex immunopathology. Affected patients often present with cellular immune deficiency and an imbalanced interplay between pro-inflammatory and anti-inflammatory mediators, with infection-immunity disequilibrium driving disease progression. The initial infection triggers a defense-injury cascade: while inflammation facilitates pathogen clearance, persistent or excessive activation leads to progressive lung tissue damage. Recent advances have deepened our understanding of immune mechanisms and inflammatory regulation; however, key challenges persist in clinical translation. Here, we synthesize current evidence on the immunopathology of severe pneumonia-associated lung injury, dissect the hierarchical architecture of its molecular regulatory networks, and critically appraise existing therapeutic strategies and their limitations. We propose a translational framework-encompassing mechanistic research, network modelling, and precision intervention-to guide stage-specific regulation and targeted therapy. Finally, we outline the major challenges impeding the clinical application of basic immunological discoveries and highlight future directions for improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.